|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0382781B1
(en)
|
1987-10-23 |
1993-09-29 |
Genetics Institute, Inc. |
Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
ATE195553T1
(de)
|
1992-06-09 |
2000-09-15 |
Chiron Corp |
Kristallisierung von m-csf
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
JPH10218791A
(ja)
|
1997-01-31 |
1998-08-18 |
Toagosei Co Ltd |
慢性関節リウマチ治療薬
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999029345A1
(en)
|
1997-12-05 |
1999-06-17 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
EP1125584A4
(en)
|
1998-10-30 |
2005-01-12 |
Takeda Chemical Industries Ltd |
PREPARATIONS CONTAINING BETACELLULIN PROTEIN
|
|
EP1176981B1
(en)
|
1999-05-07 |
2005-11-30 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
WO2001030381A2
(de)
|
1999-10-28 |
2001-05-03 |
Hofbauer, Reinhold |
Verwendung von csf-1-inhibitoren
|
|
AU1759501A
(en)
|
1999-11-08 |
2001-06-06 |
Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
WO2002102973A2
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
SI1572106T1
(sl)
|
2002-11-15 |
2010-08-31 |
Novartis Vaccines & Diagnostic |
Postopki za preprečevanje in zdravljenje rakavih metastaz in izgube kosti, povezane z rakavimi metastazami
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
DK1678314T3
(da)
|
2003-10-22 |
2012-12-03 |
Keck Graduate Inst |
Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
JP2007524671A
(ja)
|
2004-01-21 |
2007-08-30 |
カイロン コーポレイション |
Ｍ−ｃｓｆムテインおよびその使用
|
|
JP2008506366A
(ja)
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
|
WO2006012451A2
(en)
|
2004-07-22 |
2006-02-02 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for mgd-csf in disease treatment
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
DE602006011574D1
(de)
|
2005-01-27 |
2010-02-25 |
Five Prime Therapeutics Inc |
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
JP2009515521A
(ja)
|
2005-11-10 |
2009-04-16 |
レセプター バイオロジックス， インコーポレイテッド |
レセプターアイソフォームおよびリガンドアイソフォームの産生のための方法
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
CA2634945A1
(en)
|
2005-12-22 |
2007-10-25 |
Novartis Ag |
Soluble human m-csf receptor and uses thereof
|
|
KR20080083187A
(ko)
|
2006-01-05 |
2008-09-16 |
노바르티스아게 |
암 전이 및 암 전이와 관련된 골 소실의 예방 및 치료 방법
|
|
WO2007130646A2
(en)
|
2006-05-04 |
2007-11-15 |
The Rockefeller University |
Hcv coreceptor and methods of use thereof
|
|
US7833789B2
(en)
|
2006-08-01 |
2010-11-16 |
Fondazione Centro San Raffaele Del Monte Tabor |
Monocyte cell
|
|
JP2010510219A
(ja)
|
2006-11-17 |
2010-04-02 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
アミロイド関連障害を処置するためのコロニー刺激因子の全身投与
|
|
WO2008100995A1
(en)
|
2007-02-14 |
2008-08-21 |
Vaccinex, Inc. |
Humanized anti-cd100 antibodies
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
US20100298217A1
(en)
|
2007-05-30 |
2010-11-25 |
Evan Richard Stanley |
Csf-1r mutants
|
|
EA023555B1
(ru)
|
2007-08-21 |
2016-06-30 |
Амген Инк. |
АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ c-fms ЧЕЛОВЕКА
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
EP2215482A2
(en)
|
2007-10-31 |
2010-08-11 |
Janssen Pharmaceutica N.V. |
Biomarker for assessing response to fms treatment
|
|
JPWO2009075344A1
(ja)
|
2007-12-12 |
2011-04-28 |
独立行政法人国立がん研究センター |
Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
CN101970496B
(zh)
|
2008-03-14 |
2014-04-16 |
特朗斯吉有限公司 |
针对csf-1r的抗体
|
|
US8080246B2
(en)
|
2008-11-26 |
2011-12-20 |
Five Prime Therapeutics, Inc. |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
|
|
US8183207B2
(en)
|
2008-11-26 |
2012-05-22 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
|
|
HUE026201T2
(en)
|
2009-12-10 |
2016-05-30 |
Hoffmann La Roche |
Antibodies binding to human CSF1R extracellular domain 4 and their use
|
|
EP2542587A1
(en)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
|
WO2011131407A1
(en)
|
2010-03-05 |
2011-10-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
SG185035A1
(en)
*
|
2010-05-04 |
2012-11-29 |
Five Prime Therapeutics Inc |
Antibodies that bind csf1r
|
|
TW201307845A
(zh)
|
2010-12-13 |
2013-02-16 |
Novartis Ag |
預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
|
|
JP6005751B2
(ja)
|
2011-10-21 |
2016-10-12 |
トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． |
マクロファージの活性化の調節
|
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
|
JP2015517490A
(ja)
*
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
WO2014036357A1
(en)
*
|
2012-08-31 |
2014-03-06 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
WO2016069727A1
(en)
*
|
2014-10-29 |
2016-05-06 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|